Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis

NCT07039916 is registered in ClinicalTrials.gov with Immunovant Sciences GmbH as lead sponsor.

NCT NCT07039916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07039916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
Lead sponsor
Immunovant Sciences GmbH
Phase
Phase 3
Overall status
Recruiting
Start date
May 27, 2025
Completion date
December 31, 2028
Enrollment
231 (estimated)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis